Search
for
Sort by
Research 811–840 of 1000+
- Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- ROCK inhibitor Y-27632 maintains the propagation and characteristics of hair follicle stem cells.
- Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
- Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
- EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
- Abstract 1677: Epithelial hyperplasia induced by a selective B-Raf inhibitor, WYE-130600
- Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
- Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
- Letter to the Editor: A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Healthcare System
- Hair growth promotion by Necrostatin-1s
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Turning JAK STATic, a peek into the future of dermatology therapeutics
- IN-SILICO STUDY OF BIOACTIVE COMPOUNDS OF NATURAL MATERIALS AS A JAK- SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION INHIBITOR FOR ANTI-ALOPECIA
- 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
- 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
- JAK inhibitors in dermatology: The promise of a new drug class
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Tofacitinib therapy for children with severe alopecia areata